{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T05:56:58Z","timestamp":1778392618188,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.therap.2020.12.009","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T20:24:37Z","timestamp":1607113477000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)"],"prefix":"10.1016","volume":"76","author":[{"given":"Louise","family":"Carton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika\u00efl","family":"Nourredine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.12.009_bib0315","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0320","series-title":"Neuropsychopharmacologie","first-page":"2","author":"Bordet","year":"2019"},{"key":"10.1016\/j.therap.2020.12.009_bib0325","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euroneuro.2013.08.004","article-title":"A proposal for an updated neuropsychopharmacological nomenclature","volume":"24","author":"Zohar","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0330","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/0269881116642903","article-title":"Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology","volume":"30","author":"Nutt","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/npr2.12028","article-title":"Anticraving therapy for alcohol use disorder: a clinical review","volume":"38","author":"Shen","year":"2018","journal-title":"Neuropsychopharmacol Rep"},{"key":"10.1016\/j.therap.2020.12.009_bib0340","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/00952990.2010.505991","article-title":"Heroin anticraving medications: a systematic review","volume":"36","author":"Fareed","year":"2010","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.therap.2020.12.009_bib0345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.therap.2020.12.009_bib0350","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bbr.2011.01.050","article-title":"Acetylcholine: future research and perspectives","volume":"221","author":"Van der Zee","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.therap.2020.12.009_bib0355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1360-0443.1991.tb01803.x","article-title":"Behavioural pharmacology of nicotine: multiple mechanisms","volume":"86","author":"Stolerman","year":"1991","journal-title":"Br J Addict"},{"key":"10.1016\/j.therap.2020.12.009_bib0360","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/7854_2020_139","article-title":"Cholinergic receptors and addiction","volume":"45","author":"Papke","year":"2020","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.therap.2020.12.009_bib0365","first-page":"CD013308","article-title":"Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation","volume":"4","author":"Lindson","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2020.12.009_bib0370","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1001\/jama.1992.03490190087036","article-title":"Tobacco dependence and the nicotine patch. Clinical guidelines for effective use","volume":"268","author":"Fiore","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.12.009_bib0375","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"5","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2020.12.009_bib0380","first-page":"CD010078","article-title":"Pharmacological interventions for promoting smoking cessation during pregnancy","volume":"3","author":"Claire","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2020.12.009_bib0385","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1136\/tobaccocontrol-2016-053060","article-title":"How do consumers perceive differences in risk across nicotine products? A review of relative risk perceptions across smokeless tobacco, e-cigarettes, nicotine replacement therapy and combustible cigarettes","volume":"26","author":"Czoli","year":"2017","journal-title":"Tob Control"},{"issue":"5","key":"10.1016\/j.therap.2020.12.009_bib0390","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/03007995.2020.1729708","article-title":"Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations","volume":"36","author":"Tonstad","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.therap.2020.12.009_bib0395","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00213-007-1041-3","article-title":"Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt","volume":"197","author":"West","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2020.12.009_bib0400","series-title":"CHAMPIX (varenicline), brain nicotinic receptor partial agonist Transparency Committee Opinion","first-page":"1","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2016"},{"key":"10.1016\/j.therap.2020.12.009_bib0405","series-title":"StatPearls","first-page":"1","article-title":"GABA receptor. 2020 Jul 26","author":"Allen","year":"2020"},{"key":"10.1016\/j.therap.2020.12.009_bib0410","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/cns.12489","article-title":"Pharmacotherapy for alcohol dependence: The 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies","volume":"22","author":"Rolland","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.therap.2020.12.009_bib0415","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: time for a reappraisal?","volume":"26","author":"Chick","year":"2012","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.therap.2020.12.009_bib0420","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/JCP.0000000000000786","article-title":"Thirty- versus ten-day diazepam treatment for alcohol detoxification and a comparison of drinking patterns, craving, and anxiety for up to 12 weeks: a \u201cproof-of-concept\u201d open-label randomized controlled trial","volume":"37","author":"Simioni","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0425","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: the Cagliari Statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0430","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/alcalc\/agz082","article-title":"France grants an approval to baclofen for alcohol dependence","volume":"55","author":"Rolland","year":"2020","journal-title":"Alcohol Alcohol Oxf Oxfs"},{"key":"10.1016\/j.therap.2020.12.009_bib0435","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3389\/fpsyt.2018.00708","article-title":"The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective","volume":"9","author":"de Beaurepaire","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0440","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fpsyt.2018.00367","article-title":"Safety challenges of using high dose baclofen for alcohol use disorder: a focused review","volume":"9","author":"Rolland","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0445","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40264-016-0489-7","article-title":"Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France","volume":"40","author":"Auffret","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.12.009_bib0450","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/alcalc\/ags076","article-title":"A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol","volume":"47","author":"Rolland","year":"2012","journal-title":"Alcohol Alcohol Oxf Oxfs"},{"key":"10.1016\/j.therap.2020.12.009_bib0455","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/164_2018_104","article-title":"Multifunctional opioid ligands","volume":"247","author":"Anand","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0460","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2008.05.012","article-title":"Shell\/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens","volume":"55","author":"Hip\u00f3lito","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2020.12.009_bib0465","doi-asserted-by":"crossref","first-page":"107996","DOI":"10.1016\/j.neuropharm.2020.107996","article-title":"Learned avoidance requires VTA KOR-mediated reductions in dopamine","volume":"167","author":"Robble","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2020.12.009_bib0470","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.therap.2020.12.009_bib0475","series-title":"Naltrexone for opioid use disorders: a review of clinical effectiveness, cost-effectiveness and guidelines","first-page":"1","author":"Jahagirdar","year":"2017"},{"key":"10.1016\/j.therap.2020.12.009_bib0480","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.12.009_bib0485","series-title":"Clinical use of extended-release injectable naltrexone in the treatment of opioid use disorder: a brief guide","first-page":"1","author":"Substance Abuse","year":"2014"},{"key":"10.1016\/j.therap.2020.12.009_bib0490","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","article-title":"Naltrexone depot formulations for opioid and alcohol dependence: a systematic review","volume":"17","author":"Lobmaier","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.therap.2020.12.009_bib0495","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.therap.2020.12.009_bib0500","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0505","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.therap.2020.12.009_bib0510","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17425247.2019.1649252","article-title":"What place for prolonged-release buprenorphine depot-formulation Buvidal\u00ae in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine","volume":"16","author":"Vorspan","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.therap.2020.12.009_bib0515","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0520","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.therap.2020.12.009_bib0525","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J Addict Med"},{"key":"10.1016\/j.therap.2020.12.009_bib0530","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.therap.2020.12.009_bib0535","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr Drug Abuse Rev"},{"issue":"5","key":"10.1016\/j.therap.2020.12.009_bib0540","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","article-title":"Prolonged-release buprenorphine formulations: perspectives for clinical practice","volume":"75","author":"Chappuy","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2020.12.009_bib0545","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","article-title":"Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy","volume":"100","author":"Eder","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2020.12.009_bib0550","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2020.12.009_bib0555","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1527-3458.2003.tb00260.x","article-title":"Pharmacology of acamprosate: an overview","volume":"9","author":"Zornoza","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.therap.2020.12.009_bib0560","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0565","first-page":"CD000031","article-title":"Antidepressants for smoking cessation","volume":"4","author":"Howes","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.therap.2020.12.009_bib0570","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.therap.2020.12.009_bib0575","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.12.009_bib0580","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fphar.2019.00627","article-title":"Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain","volume":"10","author":"De Ternay","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.therap.2020.12.009_bib0585","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0590","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40263-016-0373-0","article-title":"Naltrexone: a pan-addiction treatment?","volume":"30","author":"Aboujaoude","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2020.12.009_bib0595","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrn3939","article-title":"The dopamine theory of addiction: 40 years of highs and lows","volume":"16","author":"Nutt","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.therap.2020.12.009_bib0600","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.therap.2020.12.009_bib0605","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/add.13328","article-title":"Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials","volume":"111","author":"Singh","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.therap.2020.12.009_bib0610","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.therap.2020.12.009_bib0615","first-page":"1","article-title":"Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis","volume":"3","author":"Nourredine","year":"2020","journal-title":"CNS Spectr"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720302262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720302262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:54:10Z","timestamp":1758567250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720302262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0040595720302262"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.009","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}